A Case of ALK-Rearranged Inflammatory Myofibroblastic Tumor of the Bladder with Remarkable Response to ALK Inhibitor

被引：0
|
作者：
Sakai, Yuta [1 ]
Ikawa, Yasuhiro [1 ]
Takenaka, Mika [1 ]
Noguchi, Kazuhiro [1 ]
Fujiki, Toshihiro [1 ]
Kuroda, Rie [1 ]
Nomura, Kozo [2 ]
Sakai, Seisho [2 ]
Wada, Taizo [1 ]
机构：
[1] Kanazawa Univ Hosp, Dept Pediat, Kanazawa, Ishikawa, Japan
[2] Kanazawa Univ Hosp, Dept Pediat Surg, Kanazawa, Ishikawa, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS19-12
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
    Butrynski, James E.
    D'Adamo, David R.
    Hornick, Jason L.
    Dal Cin, Paola
    Antonescu, Cristina R.
    Jhanwar, Suresh C.
    Ladanyi, Marc
    Capelletti, Marzia
    Rodig, Scott J.
    Ramaiya, Nikhil
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Wilner, Keith D.
    Christensen, James G.
    Jaenne, Pasi A.
    Maki, Robert G.
    Demetri, George D.
    Shapiro, Geoffrey I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18): : 1727 - 1733
  • [2] Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
    Nagumo, Yoshiyuki
    Maejima, Aiko
    Toyoshima, Yuta
    Komiyama, Motokiyo
    Yonemori, Kan
    Yoshida, Akihiko
    Fujimoto, Hiroyuki
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 48 : 1 - 4
  • [3] Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor
    Xavier, C.
    Canedo, F.
    Lima, F.
    Melo, R.
    Lima, L. G.
    Marin, J. F.
    Souza, C.
    Feher, O.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S661 - S662
  • [4] ALK-rearranged Inflammatory Myofibroblastic Tumor of the Placenta, With Observations on Site of Origin
    Schoolmeester, J. Kenneth
    Sukov, William R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2017, 36 (03) : 228 - 229
  • [5] ALK-rearranged inflammatory myofibroblastic tumour of placental membranes
    Squires, Lisa
    Matsika, Admire
    Turner, Jessica
    Fitness, Jodie
    Lourie, Rohan
    PATHOLOGY, 2018, 50 (07) : 777 - 779
  • [6] Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl
    Gaudichon, Jeremie
    Jeanne-Pasquier, Corinne
    Deparis, Marianna
    Veyssiere, Alexis
    Heyndrickx, Maxime
    Minckes, Odile
    Orbach, Daniel
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (04) : 308 - 311
  • [7] A selective ALK inhibitor in ALK-rearranged patients
    Yang, James Chih-Hsin
    LANCET ONCOLOGY, 2013, 14 (07): : 564 - 565
  • [8] Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
    Ono, Akira
    Murakami, Haruyasu
    Serizawa, Masakuni
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Taira, Tetsuhiko
    Koh, Yasuhiro
    Ohde, Yasuhisa
    Nakajima, Takashi
    Endo, Masahiro
    Takahashi, Toshiaki
    LUNG CANCER, 2016, 99 : 151 - 154
  • [9] Successful Treatment of a Highly Aggressive Abdominal Cavity ALK-rearranged Inflammatory Myofibroblastic Tumor with Alectinib: A Case Report
    Arakawa, Ayumu
    Yonemori, Kan
    Kumamoto, Tadashi
    Aoki, Yuki
    Sonoda, Tomoko
    Sugiyama, Masanaka
    Ishimaru, Sae
    Shirakawa, Nami
    Umeda, Katsutugu
    Okajima, Hideaki
    Adachi, Souichi
    Ogawa, Chitose
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S40 - S40
  • [10] ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
    Sebastian Y. F. Michels
    Andreas H. Scheel
    Thomas Wündisch
    Johannes M. Heuckmann
    Roopika Menon
    Michael Puesken
    Carsten Kobe
    Helen Pasternack
    Carina Heydt
    Matthias Scheffler
    Rieke Fischer
    Anne M. Schultheis
    Sabine Merkelbach-Bruse
    Lukas Heukamp
    Reinhard Büttner
    Jürgen Wolf
    npj Precision Oncology, 1
12345